Get started
Author

Alessandra Raimondi

Observed names: A. R. Raimondi, A. Raimondi, Raimondi, Alessandra
ORCID: 0000-0002-8999-2899
Observed ORCID: 0000-0002-8999-2899
OpenAlex ID: A5016209410
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
2019 · Filippo Pietrantonio, Rosalba Miceli, et al. · Journal of Clinical Oncology · 491
PDF
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
2019 · on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Elena Verzoni, et al. · Journal for ImmunoTherapy of Cancer · 140
PDF
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
2022 · Federica Morano, Alessandra Raimondi, et al. · Journal of Clinical Oncology · 134
PDF
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
2018 · Francesca Corti, Federico Nichetti, et al. · Cancer Treatment Reviews · 129
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer
2019 · Filippo Pietrantonio, Federica Morano, et al. · JAMA Oncology · 113
PDF
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
2019 · Federica Morano, Salvatore Corallo, et al. · Journal of Clinical Oncology · 111
INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).
2023 · Filippo Pietrantonio, Alessandra Raimondi, et al. · Journal of Clinical Oncology · 94
PDF
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
2020 · Alessandra Raimondi, Pierangela Sepe, et al. · Frontiers in Oncology · 74
PDF
Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
2022 · A.G. Leone, F. Petrelli, et al. · ESMO Open · 69
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
2019 · Giovanni Randon, Giovanni Fucà, et al. · Scientific Reports · 68
PDF
Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives
2018 · Claudio Vernieri, Federico Nichetti, et al. · Critical Reviews in Oncology/Hematology · 63
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
2024 · Carlotta Antoniotti, Daniele Rossini, et al. · Journal of Clinical Oncology · 62
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial
2019 · Maria Di Bartolomeo, Federica Morano, et al. · The Oncologist · 57
The Landscape of Actionable Gene Fusions in Colorectal Cancer
2019 · Filippo Pagani, Giovanni Randon, et al. · International Journal of Molecular Sciences · 56
PDF
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
2019 · Giuseppe Procopio, Giulia Apollonio, et al. · European Urology Oncology · 55
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
2021 · Alessandra Raimondi, Federica Palermo, et al. · Cancers · 54
PDF
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
2020 · Filippo Pietrantonio, Fotios Loupakis, et al. · The Oncologist · 51
Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study
2018 · Augusto Caraceni, Raffaella Speranza, et al. · Journal of Pain and Symptom Management · 46
PDF
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
2023 · Sara Lonardi, Cosimo Rasola, et al. · Journal of Clinical Oncology · 41
PDF
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial
2019 · Rosalba Miceli, Jiyeong An, et al. · Oncology · 41
Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population
2019 · Giorgia Peverelli, Alessandra Raimondi, et al. · Clinical Genitourinary Cancer · 38
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
2018 · F. Morano, S. Corallo, et al. · Annals of Oncology · 37
PDF
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
2021 · Paolo Manca, Salvatore Corallo, et al. · British Journal of Cancer · 36
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2019 · Filippo Pietrantonio, Riccardo Lobefaro, et al. · Clinical Cancer Research · 32
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
2021 · Giovanni Fucà, Francesca Corti, et al. · Journal for ImmunoTherapy of Cancer · 31
PDF
Works count: 233
Citation count: 2,994
H-index: 27
I10-index: 63
Year
Topic
Type